Market News

Ghost Tree Capital Has Lowered Its Genmark Diagnostics (GNMK) Holding by $1.80 Million as Share Value Rose; Achillion Pharmaceuticals (ACHN) Market Value Rose While Sarissa Capital Management LP Increased Stake

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Logo

Ken Greenberg decreased its stake in Genmark Diagnostics Inc (GNMK) by 47.37% based on its latest 2017Q4 regulatory filing with the SEC. Ghost Tree Capital Llc sold 450,000 shares as the company’s stock rose 18.14% while stock markets declined. The hedge fund run by Ken Greenberg held 500,000 shares of the health care company at the end of 2017Q4, valued at $2.09 million, down from 950,000 at the end of the previous reported quarter. Ghost Tree Capital Llc who had been investing in Genmark Diagnostics Inc for a number of months, seems to be less bullish one the $344.67 million market cap company. The stock decreased 3.57% or $0.23 during the last trading session, reaching $6.22. About 182,554 shares traded. GenMark Diagnostics, Inc. (NASDAQ:GNMK) has declined 59.05% since April 19, 2017 and is downtrending. It has underperformed by 70.60% the S&P500.

Alex Denner increased its stake in Achillion Pharmaceuticals Inc (ACHN) by 17% based on its latest 2017Q4 regulatory filing with the SEC. Sarissa Capital Management Lp bought 363,200 shares as the company’s stock rose 28.04% while stock markets declined. The hedge fund run by Alex Denner held 2.50 million shares of the health care company at the end of 2017Q4, valued at $7.20M, up from 2.14M at the end of the previous reported quarter. Sarissa Capital Management Lp who had been investing in Achillion Pharmaceuticals Inc for a number of months, seems to be bullish on the $501.93M market cap company. The stock decreased 1.36% or $0.05 during the last trading session, reaching $3.64. About 317,563 shares traded. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 2.57% since April 19, 2017 and is downtrending. It has underperformed by 14.12% the S&P500.

Investors sentiment increased to 2.08 in Q4 2017. Its up 1.12, from 0.96 in 2017Q3. It increased, as 10 investors sold ACHN shares while 28 reduced holdings. 34 funds opened positions while 45 raised stakes. 110.36 million shares or 4.96% more from 105.14 million shares in 2017Q3 were reported. Artal Grp Inc Inc owns 750,000 shares. Ubs Asset Americas holds 64,639 shares or 0% of its portfolio. Dafna Capital Mngmt Ltd Liability reported 1.47% stake. Arrowmark Colorado Holdg Ltd, Colorado-based fund reported 935,987 shares. Integral Derivatives Ltd Liability owns 15,368 shares. Susquehanna Gru Llp reported 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Walleye Trading Ltd Liability Corp, Minnesota-based fund reported 45,600 shares. Art Limited Liability Com accumulated 133,113 shares. Cubist Systematic Strategies Limited Liability Company holds 17,692 shares. 10,118 were reported by Ameritas Inv Partners. Gsa Cap Prns Limited Liability Partnership has invested 0.02% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). National Bank Of Montreal Can invested 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Sarissa Cap Mgmt LP invested in 2.50 million shares or 1.84% of the stock. Parallax Volatility Advisers LP reported 18,312 shares or 0% of all its holdings. Blair William & Il reported 0% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

Among 11 analysts covering Achillion Pharma (NASDAQ:ACHN), 6 have Buy rating, 0 Sell and 5 Hold. Therefore 55% are positive. Achillion Pharma had 27 analyst reports since August 13, 2015 according to SRatingsIntel. The firm has “Sell” rating by Chardan Capital Markets given on Friday, September 23. FBR Capital initiated the shares of ACHN in report on Thursday, September 15 with “Outperform” rating. The company was downgraded on Friday, January 29 by Leerink Swann. The stock has “Buy” rating by Maxim Group on Thursday, August 13. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) earned “Outperform” rating by Wedbush on Friday, September 23. The firm has “Hold” rating given on Monday, October 23 by Robert W. Baird. The firm has “Market Outperform” rating by JMP Securities given on Thursday, July 7. The stock of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) earned “Buy” rating by Maxim Group on Wednesday, August 9. FBR Capital initiated Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) rating on Wednesday, February 7. FBR Capital has “Hold” rating and $3.5 target. UBS upgraded the stock to “Buy” rating in Tuesday, September 8 report.

Since January 23, 2018, it had 1 buy, and 26 selling transactions for $311,956 activity. The insider Stier Eric sold 1,996 shares worth $8,723. Shares for $72,141 were sold by MASSARANY HANY. 4,911 shares were sold by Williams Jennifer Anne, worth $20,479. Mendel Scott sold $1,324 worth of GenMark Diagnostics, Inc. (NASDAQ:GNMK) on Friday, February 2. On Friday, February 23 Mitchell Brian Andrew sold $4,387 worth of GenMark Diagnostics, Inc. (NASDAQ:GNMK) or 1,052 shares. On Friday, February 2 the insider McNally James B. sold $4,350.

Ghost Tree Capital Llc, which manages about $426.44 million US Long portfolio, upped its stake in Alexion Pharmaceuticals Inc (NASDAQ:ALXN) by 15,000 shares to 115,000 shares, valued at $13.75M in 2017Q4, according to the filing. It also increased its holding in Incyte Corp (NASDAQ:INCY) by 15,000 shares in the quarter, for a total of 50,000 shares, and has risen its stake in Spdr Series Trust (Put) (XBI).

Analysts await GenMark Diagnostics, Inc. (NASDAQ:GNMK) to report earnings on May, 1. They expect $-0.21 EPS, up 30.00% or $0.09 from last year’s $-0.3 per share. After $-0.26 actual EPS reported by GenMark Diagnostics, Inc. for the previous quarter, Wall Street now forecasts -19.23% EPS growth.

Among 6 analysts covering Genmark Diagnostics (NASDAQ:GNMK), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Genmark Diagnostics had 20 analyst reports since October 14, 2015 according to SRatingsIntel. The stock of GenMark Diagnostics, Inc. (NASDAQ:GNMK) has “Buy” rating given on Monday, October 30 by Canaccord Genuity. The firm has “Market Perform” rating given on Friday, November 3 by Raymond James. The rating was maintained by Needham on Wednesday, August 30 with “Buy”. The rating was maintained by Canaccord Genuity on Monday, September 25 with “Buy”. Needham maintained it with “Buy” rating and $13 target in Wednesday, October 28 report. Needham maintained GenMark Diagnostics, Inc. (NASDAQ:GNMK) rating on Monday, June 12. Needham has “Buy” rating and $1700 target. Needham maintained the shares of GNMK in report on Friday, January 19 with “Buy” rating. Canaccord Genuity maintained it with “Buy” rating and $1400 target in Monday, August 7 report. The company was maintained on Wednesday, February 28 by Canaccord Genuity. The rating was maintained by Needham with “Buy” on Wednesday, August 2.

Investors sentiment decreased to 1.26 in Q4 2017. Its down 0.62, from 1.88 in 2017Q3. It dropped, as 14 investors sold GNMK shares while 21 reduced holdings. 18 funds opened positions while 26 raised stakes. 53.33 million shares or 5.73% less from 56.57 million shares in 2017Q3 were reported. Ubs Asset Management Americas Inc owns 49,400 shares. Ontario – Canada-based Manufacturers Life Ins The has invested 0% in GenMark Diagnostics, Inc. (NASDAQ:GNMK). Millennium Management Ltd Liability Corp invested 0% of its portfolio in GenMark Diagnostics, Inc. (NASDAQ:GNMK). Susquehanna Int Gp Llp reported 0% stake. Glenmede Na reported 1,000 shares. Ny State Common Retirement Fund holds 0% or 46,400 shares. Barclays Public Limited Company invested 0% of its portfolio in GenMark Diagnostics, Inc. (NASDAQ:GNMK). 50,190 were reported by Art Advisors Ltd Company. Morgan Stanley reported 719,168 shares or 0% of all its holdings. Northern Trust holds 0% of its portfolio in GenMark Diagnostics, Inc. (NASDAQ:GNMK) for 698,528 shares. California State Teachers Retirement Systems has 81,096 shares. D E Shaw & Incorporated invested 0% of its portfolio in GenMark Diagnostics, Inc. (NASDAQ:GNMK). Prelude Capital Limited Liability Company holds 600 shares or 0% of its portfolio. Teacher Retirement System Of Texas has 0% invested in GenMark Diagnostics, Inc. (NASDAQ:GNMK). Putnam Investments Ltd Llc reported 4.08 million shares.

GenMark Diagnostics, Inc. (NASDAQ:GNMK) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *